June 19th 2025
Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.
Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM
Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge
Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates
Dr Kashyap Patel Discusses COVID-19 Implications for PCOC® 2020